Invivyd (NASDAQ:IVVD) Insider Sells $50,467.34 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 32,771 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $1.54, for a total value of $50,467.34. Following the sale, the insider owned 216,675 shares of the company’s stock, valued at approximately $333,679.50. This represents a 13.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Jill Andersen also recently made the following trade(s):

• On Wednesday, February 18th, Jill Andersen sold 34,939 shares of Invivyd stock. The stock was sold at an average price of $1.58, for a total value of $55,203.62.

Invivyd Trading Down 3.7%

NASDAQ IVVD opened at $1.55 on Friday. The company has a market cap of $361.34 million, a P/E ratio of -3.30 and a beta of 0.60. The company has a fifty day simple moving average of $2.16 and a 200 day simple moving average of $1.76. Invivyd, Inc. has a 12-month low of $0.46 and a 12-month high of $3.07.

Analyst Upgrades and Downgrades

IVVD has been the subject of several recent research reports. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. HC Wainwright increased their price target on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.00.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IVVD. Invesco Ltd. lifted its holdings in shares of Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after acquiring an additional 71,485 shares during the last quarter. AQR Capital Management LLC boosted its stake in Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after acquiring an additional 391,617 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Invivyd during the second quarter worth about $27,000. Finally, Marshall Wace LLP purchased a new position in Invivyd during the 2nd quarter worth approximately $158,000. 70.36% of the stock is owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.